Dimitris Agrafiotis, PhD

Dimitris Agrafiotis, PhD, FRSC, is a Partner at Arsenal Capital Partners, where he’s responsible for shaping the digital, data, and AI strategy for the healthcare franchise. Dr. Agrafiotis’ expertise lies at the intersection of digital technology, computational and data science, and life sciences and spans the entire R&D continuum across venture-funded biotech, big pharma, and the services industry. Prior to Arsenal, Dr. Agrafiotis served as Chief Digital Officer for Generate Biomedicines, Vice President of Digital for Worldwide Research, Development and Medical for Pfizer, Chief Information Officer for the Novartis Institutes for Biomedical Research, Chief Data Officer and Head of Technology Products for Covance/LabCorp, and Vice President of Research and Early Development Informatics and IT for Johnson & Johnson (J&J). Prior to J&J, he spent ten years at biotech startup 3-Dimensional Pharmaceuticals, from its founding to its IPO and eventual acquisition by J&J. He started his career as a Senior Scientist in the Computer-Aided Drug Design group at Parke-Davis. Dr. Agrafiotis received his BS in chemistry from the University of Patras and PhD in theoretical chemistry from Imperial College London and held postdoctoral fellowships at the University of California at Berkeley and Harvard University, where he worked with Nobel laureate EJ Corey. His work is documented in more than 100 peer-reviewed publications and book chapters and 18 issued US patents, and he’s ranked among the world’s 1% most cited scientists. In 2012 he was elected Fellow of the Royal Society of Chemistry for his contributions to chemical and pharmaceutical research, and in 2016 he was named in Computerworld’s Premier 100 Technology Leaders for his technology leadership and innovative approaches to business challenges.